Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (611-620 of 962) with videos related to

Pageof 97
Sort By:
Journal of the American College of Cardiology|October 9, 2024
Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 ResultsGregg W Stone, Marco Valgimigli, David Erlinge, et al.
European Journal of Preventive Cardiology|June 16, 2022
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumabUlf Landmesser, Jennifer McGinniss, Ph Gabriel Steg, et al.
Circulation|September 9, 2010
Attained educational level and incident atherothrombotic events in low- and middle-income compared with high-income countriesAbhinav Goyal, Deepak L Bhatt, P Gabriel Steg, et al.
JAMA|September 1, 2010
Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial, Philippe Gabriel Steg, Sanjit S Jolly, et al.
American Heart Journal|April 1, 2019
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trialGregory Y H Lip, Laura Mauri, Gilles Montalescot, et al.
European Heart Journal|September 25, 2015
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIXJ Antonio Gutierrez, Robert A Harrington, James C Blankenship, et al.
Clinical Cardiology|January 6, 2021
Restrictive vs liberal red blood cell transfusion strategies in patients with acute myocardial infarction and anemia: Rationale and design of the REALITY trialGregory Ducrocq, Gonzalo Calvo, José Ramón González-Juanatey, et al.
Circulation. Cardiovascular Interventions|December 17, 2021
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIXMatthew A Cavender, Robert A Harrington, Gregg W Stone, et al.
American Heart Journal|April 30, 2017
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromesGregory Ducrocq, Phillip J Schulte, Andrzej Budaj, et al.
BMJ Open|July 3, 2024
Assessment of smoking care by stroke specialists in patients with recent TIA and minor stroke: an international prospective registry-based cohort studyPhilippa Lavallee, Hugo Charles, Julien Labreuche, et al.
Pageof 97

Showing results (611-620 of 962) with videos related to

Sort By:
Pageof 97
Journal of the American College of Cardiology|October 9, 2024
Bivalirudin vs Heparin Anticoagulation in STEMI: Confirmation of the BRIGHT-4 ResultsGregg W Stone, Marco Valgimigli, David Erlinge, et al.
European Journal of Preventive Cardiology|June 16, 2022
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumabUlf Landmesser, Jennifer McGinniss, Ph Gabriel Steg, et al.
Circulation|September 9, 2010
Attained educational level and incident atherothrombotic events in low- and middle-income compared with high-income countriesAbhinav Goyal, Deepak L Bhatt, P Gabriel Steg, et al.
JAMA|September 1, 2010
Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial, Philippe Gabriel Steg, Sanjit S Jolly, et al.
American Heart Journal|April 1, 2019
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trialGregory Y H Lip, Laura Mauri, Gilles Montalescot, et al.
European Heart Journal|September 25, 2015
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIXJ Antonio Gutierrez, Robert A Harrington, James C Blankenship, et al.
Clinical Cardiology|January 6, 2021
Restrictive vs liberal red blood cell transfusion strategies in patients with acute myocardial infarction and anemia: Rationale and design of the REALITY trialGregory Ducrocq, Gonzalo Calvo, José Ramón González-Juanatey, et al.
Circulation. Cardiovascular Interventions|December 17, 2021
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIXMatthew A Cavender, Robert A Harrington, Gregg W Stone, et al.
American Heart Journal|April 30, 2017
Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromesGregory Ducrocq, Phillip J Schulte, Andrzej Budaj, et al.
BMJ Open|July 3, 2024
Assessment of smoking care by stroke specialists in patients with recent TIA and minor stroke: an international prospective registry-based cohort studyPhilippa Lavallee, Hugo Charles, Julien Labreuche, et al.
Pageof 97